1 Universidade Estadual do Oeste do Paraná, Cascavel, Brazil.
2 Universidade Federal do Paraná, Curitiba, Brazil.
J Atten Disord. 2019 Jan;23(2):111-120. doi: 10.1177/1087054717696773. Epub 2017 Apr 3.
The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients.
Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC).
Ten ( n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]).
It was possible to generate evidence about the safety profile of different ADHD drugs.
本研究旨在分析比较治疗成人注意缺陷多动障碍（ADHD）药物的证据。
系统检索电子数据库。纳入评估 ADHD 药物安全性的随机、双盲、平行对照试验。统计分析采用两两荟萃分析和混合治疗比较（MTC）。
纳入 10 项（n=3006）试验。我们观察到以下结局存在统计学差异：阿托莫西汀与安慰剂相比，食欲减退（比值比[OR] = 0.15，95%可信区间[CrI] = [0.05，0.38]）和缓释混合安非他命盐与安慰剂（OR = 0.06，95% CrI = [0.00，0.51]）；阿托莫西汀与安慰剂相比，失眠（OR = 0.48，95% CrI = [0.27，0.88]）和缓释混合安非他命盐与安慰剂（OR = 0.23，95% CrI = [0.06，0.76]）；阿托莫西汀与哌甲酯控释片相比，嗜睡（OR = 0.24，95% CrI = [0.06，0.97]）；以及阿托莫西汀与安慰剂相比，性欲减退（OR = 0.28，95% CrI = [0.08，0.90]）。
能够生成关于不同 ADHD 药物安全性特征的证据。
